SCYNEXIS Europe is Now Selcia Following Spin Off From SCYNEXIS, Inc.
SCYNEXIS, Inc., a medicinal chemistry-focused drug discovery and development company, has sold its wholly-owned subsidiary in the United Kingdom, SCYNEXIS Europe Limited, to its U.K. management. The new company will operate under the name Selcia Limited.
Dr. Hans Fliri, the Managing Director of Selcia said, "We are pleased to have this opportunity to develop our business as the only dedicated provider of custom radiolabeling, chemistry and analytics services to a worldwide customer base."
"The continuing rapid expansion of our business has provided us with the confidence to move forward as an independent company. We are already in the process of offering new services such as metabolomics and metabolic profiling, and their integration with chemistry," Fliri continued. "Our service business is based on a track record of scientific excellence at the Ongar site and a skillful, highly committed staff. We plan to increase capacity in this business and to invest in new development programs in the future. This will create opportunities for new financial investment in the company."
Other news from the department business & finance
These products might interest you
Milli-Q® Services / MyMilli-Q™ by Merck Life Science
Services & Support for Water Purification Systems
Quality Care, Delivered. In Person & Online
Good Weighing Practice by Mettler-Toledo
Your Concrete Weighing Quality Assurance Plan
GWP Verification service
